208 related articles for article (PubMed ID: 38541124)
41. Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective study.
Domański P; Jarosińska J; Kruczyk B; Piętak M; Mydlak A; Demkow T; Kuncman Ł; Darewicz M; Sikora-Kupis B; Dumnicka P; Kucharz J
Contemp Oncol (Pozn); 2023; 27(3):190-197. PubMed ID: 38239858
[TBL] [Abstract][Full Text] [Related]
42. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
Gross-Goupil M; Bodnar L; Campbell MT; Michael A; Venugopal B; Żołnierek J; Dutailly P; Procopio G; Albiges L
Clin Genitourin Cancer; 2024 Feb; 22(1):84-97. PubMed ID: 38101983
[TBL] [Abstract][Full Text] [Related]
43. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
Wiecek W; Karcher H
PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
[TBL] [Abstract][Full Text] [Related]
44. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
45. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis.
Manz KM; Fenchel K; Eilers A; Morgan J; Wittling K; Dempke WCM
Adv Ther; 2020 Feb; 37(2):730-744. PubMed ID: 31838709
[TBL] [Abstract][Full Text] [Related]
48. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).
Chen RC; Choueiri TK; Feuilly M; Meng J; Lister J; Marteau F; Falchook AD; Morris MJ; George DJ; Feldman DR
Cancer; 2020 Dec; 126(24):5311-5318. PubMed ID: 33022096
[TBL] [Abstract][Full Text] [Related]
49. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.
Krens SD; van Erp NP; Groenland SL; Moes DJAR; Mulder SF; Desar IME; van der Hulle T; Steeghs N; van Herpen CML
BMC Cancer; 2022 Mar; 22(1):228. PubMed ID: 35236333
[TBL] [Abstract][Full Text] [Related]
50. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.
Santoni M; Massari F; Grande E; Procopio G; Matrana MR; Rizzo M; De Giorgi U; Basso U; Milella M; Iacovelli R; Aurilio G; Incorvaia L; Buti S; Caffo O; Fornarini G; Carrozza F; Mollica V; Rizzo A; Farag F; Molina-Cerrillo J; Battelli N
Target Oncol; 2021 Sep; 16(5):625-632. PubMed ID: 34338966
[TBL] [Abstract][Full Text] [Related]
51. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
[TBL] [Abstract][Full Text] [Related]
52. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
53. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
[TBL] [Abstract][Full Text] [Related]
54. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
55. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
56. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal SK; McGregor B; Suárez C; Tsao CK; Kelly W; Vaishampayan U; Pagliaro L; Maughan BL; Loriot Y; Castellano D; Srinivas S; McKay RR; Dreicer R; Hutson T; Dubey S; Werneke S; Panneerselvam A; Curran D; Scheffold C; Choueiri TK; Agarwal N
J Clin Oncol; 2021 Nov; 39(33):3725-3736. PubMed ID: 34491815
[TBL] [Abstract][Full Text] [Related]
57. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
Tran BD; Li J; Ly N; Faggioni R; Roskos L
Cancer Chemother Pharmacol; 2023 Feb; 91(2):179-189. PubMed ID: 36625894
[TBL] [Abstract][Full Text] [Related]
58. Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
Venugopal B; Pillai M; Powles T; Savage P; Michael A; Fife K; Klair B; Perrot V; Szabados B
Clin Genitourin Cancer; 2022 Feb; 20(1):94-94.e10. PubMed ID: 34802966
[TBL] [Abstract][Full Text] [Related]
59. A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
Choueiri TK; Pal SK; McDermott DF; Morrissey S; Ferguson KC; Holland J; Kaelin WG; Dutcher JP
Ann Oncol; 2014 Aug; 25(8):1603-8. PubMed ID: 24827131
[TBL] [Abstract][Full Text] [Related]
60. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]